American Kratom Association Announces Resolution of Federal MGPI Scheduling Lawsuit

The federal lawsuit challenged uncertainty surrounding trace amounts of mitragynine pseudoindoxyl in natural kratom products. New DEA thresholds may help clarify how those products are regulated.

October 16, 2026 | Kratom Industry News

The American Kratom Association (AKA) has announced the resolution of its federal lawsuit challenging the potential consequences of the Drug Enforcement Administration's (DEA) emergency scheduling of mitragynine pseudoindoxyl (MGPI).

The October 9 announcement follows a legal dispute over whether traditional botanical kratom products could face Schedule I restrictions simply because sensitive laboratory testing detects incidental trace amounts of MGPI.

The development comes as federal officials introduce new concentration-based thresholds intended to distinguish products containing relatively low levels of certain alkaloids from concentrated or chemically manipulated opioid products.

For the kratom industry, the lawsuit raises a significant question: Can a botanical product become subject to federal controlled-substance restrictions because laboratory equipment detects trace amounts of a scheduled compound?

Why Did the American Kratom Association Sue the DEA?

The dispute began following the DEA's August 26, 2026, temporary scheduling of three opioid compounds:

• Mitragynine pseudoindoxyl (MGPI)
• MGM-15
• MGM-16

The emergency action placed all three substances into Schedule I of the Controlled Substances Act.

The Department of Justice explained that the scheduling action targeted deliberately manufactured and concentrated opioid products rather than traditional botanical kratom.

However, it also acknowledged unresolved scientific questions concerning whether incidental traces of MGPI could occur in some botanical products through processing, storage, or analytical conditions.

The DOJ announced that federal authorities would exercise enforcement discretion when only incidental trace amounts of MGPI were confirmed in a product otherwise consistent with botanical kratom.

But that policy did not create a formal legal exemption.

The AKA argued that this distinction was insufficient.

The Legal Concern: Enforcement Discretion Is Not the Same as an Exemption

On August 26, the AKA filed American Kratom Association v. United States Drug Enforcement Administration, et al., Case No. 1:26-cv-02997, in the U.S. District Court for the District of Columbia.

The organization publicly announced the lawsuit on September 2.

According to the AKA, the problem was the gap between what federal officials said they intended to regulate and how the scheduling order might be interpreted or enforced.

Although DOJ officials indicated that incidental trace MGPI in otherwise botanical kratom would not be an enforcement priority, MGPI itself remained a Schedule I substance.

The AKA argued that a discretionary federal enforcement policy did not necessarily protect consumers, retailers, manufacturers, or laboratories from other enforcement actions.

The organization's lawsuit sought declaratory and injunctive relief to address that uncertainty.

Importantly, the AKA was not asking the court to overturn restrictions on intentionally manufactured or concentrated MGPI products. Its stated objective was to clarify the treatment of traditional botanical kratom containing incidental trace compounds.

What Changed in October?

On October 9, the Department of Justice announced updated scheduling actions based on new scientific recommendations from the Department of Health and Human Services (HHS).

The revised approach introduced proposed thresholds for both 7-hydroxymitragynine (7-OH) and MGPI.

Under the updated recommendations, Schedule I controls would apply when the amount of either compound, or their combined amount when both are present, exceeds:

• 1 milligram per gram in solid products.
• 1 milligram per milliliter in liquid products.
• Or a ratio threshold in which mitragynine is present at less than 100 times the amount of 7-OH, MGPI, or their combined amount.

These are alternative criteria, meaning a product could fall within the proposed controls by meeting either a concentration threshold or the ratio threshold.

The new approach is intended to recognize differences between products containing trace levels of these compounds and those containing elevated concentrations.

The DEA published its revised Notice of Intent in the Federal Register on October 14.

The thresholds remain part of an ongoing federal scheduling process and should not be interpreted as an immediate blanket exemption for natural kratom products.

AKA Announces Litigation Resolution

In its October 9 statement, the AKA welcomed the resolution of its litigation and praised the federal government's updated scheduling approach.

The organization characterized the development as an important step toward distinguishing traditional botanical kratom from chemically manipulated opioid products.

Mac Haddow, the AKA's Senior Fellow on Public Policy, described the outcome as a victory for scientifically informed regulation and consumer access.

The statement did not provide detailed settlement terms or identify a final judicial ruling establishing those distinctions.

A public docket index for the federal case shows additional activity on October 14, including a filing categorized as a dismissal. However, the available docket summary does not establish the complete terms or final procedural disposition.

The distinction is important: the AKA's announcement confirms its position that the dispute has been resolved, but it does not establish that a court ruled against the DEA or invalidated the original scheduling order.

What Does This Mean for Natural Kratom?

For consumers and businesses, the development highlights the growing importance of distinguishing traditional botanical kratom from products deliberately enhanced with concentrated alkaloids.

Traditional kratom leaf contains mitragynine and other naturally occurring compounds. Scientific analysis has established that 7-OH can occur naturally at relatively low concentrations.

The occurrence of trace MGPI in botanical kratom remains an area of developing scientific understanding.

The updated HHS recommendations acknowledge that some trace MGPI detections may occur in botanical or kratom-derived products, although additional research is needed to clarify their origins and prevalence.

The proposed thresholds are intended to account for these differences.

However, several limitations remain important.

First, the DEA's August 2026 temporary scheduling of MGPI, MGM-15, and MGM-16 remains in effect pending further federal action.

Second, the revised thresholds have not yet replaced those existing controls.

Third, the new approach does not establish that natural kratom products are FDA-approved or free from federal and state regulatory requirements.

Finally, the presence of a compound below a proposed scheduling threshold should not be interpreted as proof that a product is safe.

Why Laboratory Testing Matters

The AKA's lawsuit illustrates a broader challenge in botanical regulation: modern laboratory equipment can detect increasingly small quantities of chemical compounds.

The ability to detect a substance does not necessarily establish how or why that substance appeared in a finished product.

Its presence could reflect natural chemistry, processing conditions, storage, intentional addition, or other factors that require scientific evaluation.

For kratom manufacturers and testing laboratories, this creates a need for reliable analytical methods and accurately documented alkaloid concentrations.

Clear testing standards could help distinguish products with incidental trace levels of certain compounds from those containing deliberately elevated concentrations.

The AKA has also called for independent laboratory testing, accurate alkaloid disclosure, appropriate serving sizes, and consistent manufacturing standards.

Those recommendations reflect the organization's advocacy position rather than new legal requirements established by the lawsuit itself.

What Happens Next?

Although the AKA has announced a resolution of the litigation, federal regulation of MGPI and 7-OH continues to evolve.

The DEA must complete the applicable procedures before the revised temporary scheduling controls can take effect.

As the process advances, several questions remain:

• How will the new thresholds be incorporated into enforceable scheduling orders?
• Will future federal guidance clarify the treatment of incidental trace MGPI in botanical kratom?
• What testing methods will regulators accept for determining compliance?
• How will federal standards interact with existing state-level kratom restrictions?

The answers will have implications for product manufacturers, laboratories, retailers, and consumers.

A Legal Dispute That Highlights a Larger Regulatory Question

The AKA's lawsuit focused on a narrow but consequential issue: whether federal scheduling policy could unintentionally encompass botanical kratom products containing incidental trace amounts of MGPI.

The organization's announced resolution coincides with a revised federal approach that places greater emphasis on measurable alkaloid concentrations and ratios.

Whether those thresholds ultimately resolve every legal concern will depend on subsequent DEA actions and how the rules are implemented.

For now, the case illustrates why precise chemical definitions, reliable laboratory testing, and clearly written regulations matter.

The central issue is not simply whether a compound can be detected, but how its concentration, chemical context, and legal status should be evaluated.

As kratom regulation continues to develop, those distinctions will remain central to the discussion.